Compass CTX-471 (Advanced or Metastatic Cancer)

What is the Purpose of this Study?

If you choose to join this study, you will:
- Have an infusion of the study drug (CTX-471) once every 2 weeks
- Have a tumor biopsy
- Have an eye exam
- Have physical exams, blood and urine tests
- Have imaging scans (CT and/or MRI)
- Have tests of your heart (ECG)
What is the Condition Being Studied?
Metastatic or locally advanced cancer that did not respond to prior treatment with a PD-1 or PD-L1 inhibitor

Who Can Participate in this Study?

Adults who have metastatic or locally advanced cancer who:

- Did not respond to prior treatment with a PD-1 or PD-L1 inhibitor

- Have not had other systemic anticancer therapy

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out if an investigational drug, CTX-471, is safe and effective against your cancer.

Study Details

Full Title
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 Administered Either as a Monotherapy or in Combination with Pembrolizumab in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies
Principal Investigator

Protocol Number

View on